

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

**Ficus religiosa L. bark extracts inhibit infection by herpes simplex virus type 2 in vitro**

**This is the author's manuscript**

*Original Citation:*

*Availability:*

This version is available <http://hdl.handle.net/2318/1634686> since 2022-01-26T11:41:15Z

*Published version:*

DOI:10.1007/s00705-016-3032-3

*Terms of use:*

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

This is the author's final version of the contribution published as:

Ghosh, Manik; Civra, Andrea; Rittà, Massimo; Cagno, Valeria; Mavuduru, Siva Ganesh; Awasthi, Preeti; Lembo, David; Donalisio, Manuela. Ficus religiosa L. bark extracts inhibit infection by herpes simplex virus type 2 in vitro. ARCHIVES OF VIROLOGY. 161 (12) pp: 3509-3514.

DOI: 10.1007/s00705-016-3032-3

The publisher's version is available at:

<http://link.springer.com/10.1007/s00705-016-3032-3>

When citing, please refer to the published version.

Link to this full text:

<http://hdl.handle.net/>

# Archives of Virology

## Ficus religiosa L. bark extracts inhibit infection by Herpes Simplex Virus type 2 in vitro --Manuscript Draft--

<b>Manuscript Number:</b>	ARVI-D-16-00281	
<b>Full Title:</b>	Ficus religiosa L. bark extracts inhibit infection by Herpes Simplex Virus type 2 in vitro	
<b>Article Type:</b>	Original Article	
<b>Corresponding Author:</b>	Manuela Donalisio, Ph. D. University of Turin Orbassano (Turin), PIEMONTE ITALY	
<b>Corresponding Author Secondary Information:</b>		
<b>Corresponding Author's Institution:</b>	University of Turin	
<b>Corresponding Author's Secondary Institution:</b>		
<b>First Author:</b>	Manik Ghosh	
<b>First Author Secondary Information:</b>		
<b>Order of Authors:</b>	Manik Ghosh	
	Andrea Civra	
	Valeria Cagno	
	Siva Ganesh Mavuduru	
	Preeti Awasthi	
	David Lembo	
	Manuela Donalisio, Ph. D.	
<b>Order of Authors Secondary Information:</b>		
<b>Funding Information:</b>	Private donation	Dr. David Lembo
<b>Abstract:</b>	<p>Ficus religiosa, a member of the Moraceae family, is the most sacred tree of South Asia and its bark extracts have been used in the traditional Indian medicine to treat sexual infections like gonorrhea and genital ulcers. The aim of this study was to investigate the antiviral activity of F. religiosa extracts against Herpes Simplex Virus type 2, the main causative agent of genital ulcers and sores. Water and chloroform bark extracts were the most active with selectivity index of 156.8 and 132.9 respectively. Of note, they were active also against an acyclovir-resistant HSV-2 strain, suggesting that their mechanism of action could be different from that of the reference drug. To this regard, we demonstrated that water bark extract has a direct virus-inactivating activity; by contrast, chloroform bark extract inhibited different steps of the viral replicative cycle, such as virus attachment and entry into cells and the cell-to-cell spread of the virus. Furthermore, chloroform bark extract limited the production of viral progeny by multiple cycles of viral replication. Our study demonstrates that F. religiosa bark extracts exert inhibitory activities against HSV-2 and support the traditional use of the plant for the treatment of genital ulcers and sores.</p>	

Dear Editor,

please find herewith attached the manuscript entitled: “*Ficus religiosa* L. bark extracts inhibit infection by Herpes Simplex Virus type 2 *in vitro*” by Ghosh et al., to be considered for publication in *Archives of Virology* as “Original Article”.

To support the traditional Indian medicinal use of *F. religiosa* extracts for the cure of ulcers and sores in venereal diseases, the present study reports for the first time a remarkable anti-HSV-2 activity of *F. religiosa* bark extracts. The main mechanism of action of extracts was also investigated. Of interest, they were active also against an acyclovir-resistant strain of HSV-2 suggesting that their mode of antiviral action is different from that of acyclovir, the prototype of conventional anti-HSV drugs. This latter feature, along with a low cytotoxicity and a favourable selectivity index make *F. religiosa* bark extracts promising starting materials for a bioguided-fractionation aimed at identifying anti-HSV-2 compounds with a novel mechanism of action that can be used against acyclovir-resistant HSV-2 strains.

For this reasons, we believe the enclosed manuscript to be suitable for publication in *Archives of Virology*.

Yours sincerely,

Dr. Manuela Donalisio, Ph.D.

Department of Clinical and Biological Sciences

University of *Torino*, S. Luigi Gonzaga Hospital

Regione Gonzole, 10

10043, Orbassano, *Torino*, Italy

Phone: +39 011 6705427

Fax: +39 011 2365427

[Click here to view linked References](#)

## ***Ficus religiosa* L. bark extracts inhibit infection by Herpes Simplex Virus type 2 *in vitro***

Manik Ghosh<sup>1</sup>, Andrea Civra<sup>2</sup>, Valeria Cagno<sup>2</sup>, Siva Ganesh Mavuduru<sup>1</sup>, Preeti Awasthi<sup>1</sup>, David Lembo<sup>2</sup>, Manuela Donalisio<sup>2\*</sup>

<sup>1</sup>*Department of Pharmaceutical Sciences & Technology, Birla Institute of Technology, Mesra, Ranchi 835215, India*

<sup>2</sup>*Department of Clinical and Biological Sciences, University of Torino, 10043 Orbassano, Torino, Italy.*

Running title: Anti-HSV-2 activity of *Ficus religiosa* L. bark extracts

\* Corresponding author: Dr. Manuela Donalisio, Ph.D.

Department of Clinical and Biological Sciences  
University of *Torino*, S. Luigi Gonzaga Hospital  
Regione Gonzole, 10  
10043, Orbassano, *Torino*, Italy  
Phone: +39 011 6705427  
Fax: +39 011 2365427  
E-mail: [manuela.donalisio@unito.it](mailto:manuela.donalisio@unito.it)

## Abstract

*Ficus religiosa*, a member of the *Moraceae* family, is the most sacred tree of South Asia and its bark extracts have been used in the traditional Indian medicine to treat sexual infections like gonorrhoea and genital ulcers. The aim of this study was to investigate the antiviral activity of *F. religiosa* extracts against Herpes Simplex Virus type 2, the main causative agent of genital ulcers and sores. Water and chloroform bark extracts were the most active with selectivity index of 156.8 and 132.9 respectively. Of note, they were active also against an acyclovir-resistant HSV-2 strain, suggesting that their mechanism of action could be different from that of the reference drug. To this regard, we demonstrated that water bark extract has a direct virus-inactivating activity; by contrast, chloroform bark extract inhibited different steps of the viral replicative cycle, such as virus attachment and entry into cells and the cell-to-cell spread of the virus. Furthermore, chloroform bark extract limited the production of viral progeny by multiple cycles of viral replication. Our study demonstrates that *F. religiosa* bark extracts exert inhibitory activities against HSV-2 and support the traditional use of the plant for the treatment of genital ulcers and sores.

**Key words:** HSV-2; antiviral; plant extract; *Ficus religiosa*

## Introduction

*Ficus religiosa* is the most popular member of the genus *Ficus* (*Moraceae*), a native of the sub-Himalayan tract, Bengal, and central India and extensively distributed worldwide through cultivation [1]. It is the most sacred tree of South Asia and its different parts have been extensively used in the traditional Hindu and South-Asian traditional systems of medicine like Ayurveda and Unani, alone or in combination with other herbs for various disorders [2]. Ethnomedical uses included treatment of diabetes, inflammation, anxiety, convulsion, epilepsy, menstrual irregularities, diarrhea, gastric problems, respiratory system, and disorders of bacterial, fungal, viral, and protozoal origin [3]. Of note, fresh plant materials or crude extracts showed some effects in treating microbial diseases associated to the respiratory tract (cough, measles, tuberculosis) gastrointestinal (ulcers, stomatitis, dysentery) and sexually transmitted infections (gonorrhea, cervical cancer) [3, 4]. In last years, different studies have been carried out to validate the antibacterial and antifungal potential of *F. religiosa*, but few findings supported its traditional use in viral disorders. Kusumoto et al [5] studied the human immunodeficiency virus-I protease inhibitory activity of the aqueous and methanolic bark extracts. Choudhari et al [4] investigated the antineoplastic potential of the aqueous extract of *F. religiosa* bark by reducing the expression of HPV oncoproteins E6 and E7 in cervical cancer cell lines and inducing cell cycle arrest and apoptosis. We have recently reported the antiviral activity of *F. religiosa* against two respiratory viruses namely Human Rhinovirus (HRV) and Respiratory Syncytial Virus (RSV) [6].

*F. religiosa* has been also used as an ethnic remedy for the cure of ulcers and sores in venereal diseases, applying burnt bark applied externally [7]. The main responsible agent of these genital lesions is the Herpes Simplex virus (HSV). Two types of HSV are known, HSV-1, and HSV-2, which are transmitted mainly through close contact. Both types may infect the genital mucosa causing genital herpes, even if HSV-1 is more frequently associated with oral and labial lesions [8]. Genital herpes is a widespread sexually transmitted infection, characterized by ulcerative lesions, often very painful and can lead to substantial psychological morbidity [9]. After a lifelong latent infection in lumbosacral sensory ganglia, periodically HSV-2 can be reactivated by external conditions (stress, hormonal changes and UV-light) and causes either asymptomatic episodes or more severe complications of the central nervous system that manifest with acute encephalitis and meningitis in neonates and immunocompromised patients [8]. Of note, HIV infection is often attributable to pre-existing HSV-2 infection, since genital ulcer disease, damaging the mucosa, induces local inflammation that may increase the risk of HIV acquisition [10]. Even if antiviral drugs targeting the viral DNA polymerase (acyclovir, penciclovir and their derivatives) are available against HSV infection, plants and herbs used in traditional medicine may represent additional sources of antiviral compounds. In this context, our study wanted to explore whether the ethnomedical use of *F. religiosa* L. to treat genital lesions is substantiated by its antiviral activity against HSV-2.

## Materials and Methods

### Plant material

The bark and leaves of *F. religiosa* L. were collected from medicinal plant garden of Birla Institute of Technology, Mesra, Ranchi and authenticated by Botanical Survey of India, Central National Herbarium, Botanical Garden, Howrah (Letter No. CNH/11/2014/ Tech.II/ dated 26-03-2014). A specimen has been deposited at the herbarium (voucher no, C-130176: PA-8).

### Preparation of extracts

The fresh bark and leaves of *F. religiosa* L. were prepared as per the method described by Cagno et al [6]. Before use for antiviral assays, extracts were resuspended in a final concentration of 25 mg/mL. Water extracts were resuspended in sterile water while other extracts were resuspended in sterile DMSO. Every experiment was performed with freshly resuspended extracts.

### Phytochemical investigations of *F. religiosa* L. extracts

The plant extracts were submitted to preliminary phytochemical screening (see Table 1). Briefly, flavonoids, tannins, saponins, alkaloids and steroids/triterpenoids, were detected by Shinoda test, FeCl<sub>3</sub>, Frothing test, Dragendorff's reagent and Salkowski test respectively [6].

**Table 1. Phytochemical analysis of *F. religiosa* L. extracts**

Source	Extract	% Yield	Saponins	Carbohydrate	Alkaloids	Flavonoids	Tannins	Steroids
Leaves	Water	6.23	+	+	-	+	-	-
	Methanol	8.41	+	-	-	+	+	+
Bark	Ethylacetate	5.27	-	-	+	-	+	-
	Water	9.26	+	+	-	+	+	-
	Chloroform	8.14	-	-	+	-	+	+
	Methanol	10.24	+	-	-	+	+	+

### Cells

African green monkey kidney cells (Vero) (ATCC CCL-81) were cultured in Eagle's minimal essential medium (MEM) (Gibco/BRL, Gaithersburg, MD) supplemented with heat inactivated 10% fetal calf serum (FCS) (Gibco/BRL) and 1% antibiotic-antimycotic solution (Zell Shield, Minerva Biolabs GmbH, Berlin, Germany), at 37°C in an atmosphere of 5% of CO<sub>2</sub>.

### Viruses

HSV-2 strain (ATCC VR-540), sensitive to acyclovir, was used for in vitro studies. HSV-2 strain with phenotypic resistance to acyclovir was generated by serial passage in the presence of increasing concentrations of acyclovir as previously described by Field et al [11]. The resistant virus was then plaque purified, and the antiviral susceptibility was tested as described in Donalisio et al [12]. Viral strains were propagated in Vero cells at 37°C in a humidified 5% CO<sub>2</sub> incubator. When the full cytopathic effect (CPE) developed, cells and supernatants were harvested, pooled, frozen and

1 thawed three times, clarified and aliquoted. Viruses were stored at  $-70^{\circ}\text{C}$ . Viral titers were determined by the standard  
2 plaque method as described previously [13].

### 3 **Cell viability**

4 Cell viability was measured by the MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-  
5 2H-tetrazolium] assay. Confluent cell cultures seeded in 96-well plates were incubated with different concentrations of  
6 extracts in triplicate under the same experimental conditions described for the antiviral assays. Cell viability was  
7 determined as described in Donalisio et al [14]. The effect on cell viability at different concentrations of the compound  
8 was expressed as a percentage, by comparing absorbances of treated cells with the ones of cells incubated with culture  
9 medium alone.

### 10 **Virus inhibition assay**

11 Inhibition of HSV replication was first evaluated with plaque reduction assay. Vero cells were seeded at  $10 \times 10^4$   
12 cells/well in 24 well plates. The medium was removed from the plates before treatment with different concentrations of  
13 extracts (from 100 to 0.13  $\mu\text{g/mL}$ ). After 2h of incubation ( $37^{\circ}\text{C}$ , 5%  $\text{CO}_2$ ), the medium was removed and infection was  
14 performed at a multiplicity of infection (MOI) of 0.001 PFU/cell in the presence of serial dilutions of the test extract for  
15 2 hours at  $37^{\circ}\text{C}$ . After incubation, cells were washed with medium twice and overlaid with a medium containing 1.2%  
16 methylcellulose (Sigma) and the plant extract. Treatment of control samples with equal volumes of solvent was  
17 performed in order to rule out the possibility of any cytotoxic effect ascribable to the solvent. The plates were incubated  
18 at  $37^{\circ}\text{C}$  for 1 day. After incubation, the plates were fixed and stained with 0.1% crystal violet in 20% ethanol and viral  
19 plaques were counted.

20 Virus yield reduction assay, was performed in the same conditions previously described in plaque reduction assay but  
21 cells were infected with HSV-2 at MOI of 0.01 PFU/cell and, after infection, cultures were exposed to the extract in  
22 medium and incubated until control cultures displayed extensive cytopathology. Supernatants from duplicates were  
23 pooled as appropriate 48 hours after infection and cell-free virus infectivity titers were determined in duplicate by the  
24 plaque assay in Vero cell monolayers. Percents of inhibition were determined by comparing the titer measured in the  
25 presence of the compounds to that measured in untreated wells.

### 26 **Virus inactivation assay**

27 Approximately  $10^5$  PFU of HSV-2 and 33  $\mu\text{g/mL}$  of water or chloroform or methanol extract were added to medium  
28 and mixed in a total volume of 100  $\mu\text{L}$ . The virus-compound mixtures were incubated for 0 or 2h at  $37^{\circ}\text{C}$  then diluted  
29 serially to the non-inhibitory concentration of test compound, and the residual viral infectivity determined by standard  
30 plaque method as described above.

### 31 **Time of addition assay**

32 Serial dilutions of extracts were added on cells 2h before infection or during infection or post-infection. After the  
33 incubation time described before, viral plaques were counted. A virus yield reduction assay was performed adding  
34 extract on cells post infection, as described previously.

### 35 **Attachment assay**

36 Serial dilutions of extracts were mixed with HSV and added to cooled cells and incubated for 2h at  $4^{\circ}\text{C}$  to ensure viral  
37 attachment but not entry. After two gentle washes, cells were overlaid with 1.2% methylcellulose medium, shifted to  
38  $37^{\circ}\text{C}$  for 24h and successively plaques were counted.

### 39 **Entry assay**

40 For entry assay, HSV at MOI of 0.01 PFU/cell was adsorbed for 2h at  $4^{\circ}\text{C}$  on pre-chilled confluent cells. Cells were  
41 then washed with cold MEM three times to remove unbound virus, treated with different concentrations of extract, and

incubated for 3h at 37°C. Un-penetrated viruses were inactivated with acidic glycine for 2 min at room temperature, as previously described [15]. Cells were then washed with warm medium three times and treated as described above for plaque reduction assay.

#### **Data analysis**

All results are presented as the mean values from three independent experiments. The 50% cytotoxic concentrations (CC<sub>50</sub>) and the half maximal effective concentration (EC<sub>50</sub>) values for inhibition curves were calculated by regression analysis using the program GraphPad Prism version 5.0 (GraphPad Software, San Diego, California, U.S.A.) to fit a variable slope-sigmoidal dose–response curve. A selectivity index (SI) was calculated by dividing the CC<sub>50</sub> by the EC<sub>50</sub> value. Virucidal assays and virus yield reduction assays were analyzed as described in Civra et al [16].

## Results

Different *F. religiosa* extracts from leaves and bark were examined *in vitro* for their antiviral activity against HSV-2. For this analysis, we used a complete protection assay in which serial dilutions of extracts, ranging from 100 µg/mL to 0.13 µg/mL, were added to the cell culture before, during, and after the infection. Acyclovir was tested in parallel as a reference drug for HSV. Table 2a shows that all extracts exerted an antiviral activity, although to a different extent, generating dose response curves. In particular, a remarkable inhibition of HSV-2 infection was exerted by water, chloroform and methanol bark extracts with EC<sub>50</sub> values of 9.76 µg/mL, 6.09 µg/mL and 5.20 µg/mL respectively. The antiviral effect was not a consequence of cytotoxicity since the CC<sub>50</sub> value of all extracts was above 800 µg/mL, with the exception of methanol bark extract with CC<sub>50</sub> value of 161.8 µg/mL. The water and chloroform bark extracts showed the most favorable selectivity index values (> 100) and were thus selected for further studies.

**Table 2a. Antiviral activity of *F. religiosa* extracts against HSV-2**

Virus	Source	Extract	EC <sub>50</sub> * (µg/mL) – 95% C.I. #	EC <sub>90</sub> § (µg/mL) – 95% C.I.	CC <sub>50</sub> † (µg/mL)	SI‡
HSV-2	Leaves	Water	30.94 (27.73-34.53)	63.83 (49.52-82.28)	>2500	>80.8
		Methanol	13.29 (9.573-18.46)	26.54 (9.69-72.65)	1058	79.6
	Bark	Ethyl acetate	14.26 (5.35-38.06)	19.95 (2.13-187.0)	1057	74.1
		Water	9.76 (7.86-12.10)	18.39 (9.72-34.78)	1530	156.8
		Chloroform	6.09 (3.17-11.69)	22.87 (5.83-89.70)	809.6	132.9
		Methanol	5.20 (3.56-7.60)	9.15 (4.08-20.55)	161.8	31.1
	Reference drug	Acyclovir	0.64 (0.48-0.86)	3.17 (1.69-5.95)	>300	>468

**Table 2b. Antiviral activity of *F. religiosa* extracts against an acyclovir resistant HSV-2 strain**

Virus	Source	Extract	EC <sub>50</sub> * (µg/mL) – 95% C.I. #	EC <sub>90</sub> § (µg/mL) – 95% C.I.	SI‡
HSV-2 acyclovir resistant strain	Bark	Water	6.70 (4.56-9.80)	27.01 (11.91-61.24)	228.36
		Chloroform	13.50 (9.96-18.30)	23.74 (8.96-62.90)	59.97

EC<sub>50</sub>\* half maximal effective concentration

C.I. # confidence interval

EC<sub>90</sub>§ 90% effective concentration

CC<sub>50</sub>† half maximal cytotoxic concentration

SI‡ selectivity index

Firstly, we assessed whether the antiviral activity of the two extracts is independent on the virus sensitivity to acyclovir (Table 2b). As expected, the resistant strain exhibited elevated EC<sub>50</sub> for acyclovir (60 µg/ml, data not shown in Table

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

2b). By contrast, it was susceptible to the water and chloroform extracts with EC<sub>50</sub> values of 6.7 µg/ml and 13.5 µg/ml respectively.

This finding stimulated us to perform a set of experiments aimed at elucidating the major mechanism of action of the extracts. The virucidal assay explored a possible direct virus-inactivating activity of extracts at a concentration that reduced almost completely virus infection (>EC<sub>90</sub>) in the previous assay. To this aim, the extract (33 µg/mL) and a virus aliquot containing 10<sup>5</sup> PFU were mixed and incubated at 37°C for 0 or 2h and then, viral samples were titrated on Vero cells at high dilutions at which extracts were no active. Fig. 1 shows that if virus/extracts mixtures were added promptly on cells without incubation, extract had no time to act on the virus and no inhibition was observed. By contrast, when the incubation was carried out for 2 hours at 37°C, water bark extract reduced significantly HSV-2 titers by 91% (P<0.05). These data indicate that the main major mode of antiviral action of water bark extract is direct virus inactivation. By contrast, the virus titers of samples treated with the chloroform extract did not significantly differ from those determined for untreated samples (P<0.05), indicating that the compound does not inactivate extracellular virus particles. This result indicates that the chloroform extract most probably targets cell-surface or intracellular events involved in essential steps of the HSV-2 replicative cycle.

To investigate the mechanism of action of chloroform extract, we performed a series of time-of-addition assays, in which the sample was added to the cells only before, or during, or after HSV-2 infection. As shown in Fig. 2, the extract did not exert an inhibitory activity at any tested concentrations when it was added 2 h prior to virus infection and then washed out before virus inoculum (pre-treatment assay). By contrast, it generated dose-response curves when added either during and post infection, with EC<sub>50</sub> values of 6.35 µg/mL and 14.04 µg/mL, respectively.

Next, we investigated whether it could interfere with the early steps of the HSV-2 replicative cycle, as virus attachment or entry. The attachment assay is an experimental condition in which the virus is allowed to bind to the surface of the host cells but do not undergo cell entry. The entry assay was conducted to assess whether the extract prevents the viral penetration into the host cells. As shown in Fig. 3, the chloroform extract inhibited both attachment and entry of virus with similar EC<sub>50</sub> of 19.94 µg/mL and 19.21 µg/mL, respectively.

Finally, we investigated the ability of the chloroform bark extract to limit the production of viral progeny by a viral yield reduction assay - a more stringent test which allows multiple cycles of viral replication to occur before measuring the production of infectious viruses. The assay was performed in two different experimental conditions: firstly adding the extract to cell culture before, during, and after the infection (Fig. 4A) and secondly only after the infection (Fig. 4B). In both cases, the extract generated dose response curves with EC<sub>50</sub> values of 11.7 µg/mL and 41.65 µg/mL respectively, indicating its ability to limit an ongoing infection.

## Discussion

*Ficus religiosa* L. (Moraceae) has been extensively used in traditional medicine for a wide range of ailments, including infectious disorders [3]. Here, we report the first study of antiviral activity of *F. religiosa* leaves and bark extracts against HSV-2, the main causative agent of genital ulcers and sores. Results of plaque reduction assays demonstrated that all extracts generated dose response curves with  $EC_{50} < 30.94$   $\mu\text{g/ml}$ . Of note, leaves water and methanol extracts of *F. religiosa* exerted a higher antiviral activity than water extract from the leaves of *Ficus carica* [17]. Phytochemical investigations demonstrated the presence of saponins and flavonoids in both water and methanol of *F. religiosa* leaves extracts. Further investigations are required to elucidate which fractions and pure compounds are endowed with antiviral activity. Interestingly, a new anti-HSV-1 triglycoside flavones was isolated from the leaves of *Ficus ischnopoda* [18] and flavones glycosides from *Ficus binjamina* leaves inhibited HSV-1, HSV-2 and Varicella Zoster virus cell infection in vitro [19]. Our results pointed out a stronger inhibitory activity of water and chloroform bark extracts of *F. religiosa* against HSV-2 infections than leaves extracts and therefore they were selected for further studies. Of note, water and chloroform bark extracts also generated dose response curves against HSV type 1, a member of alpha-herpesvirinae subfamily usually associated with oro-labial infections but also capable of infecting anogenital mucosal sites (data not shown). As reported in table 2, both extracts were able to inhibit the infection of acyclovir-resistant strain with SI of 228.36 and 59.97 for water and chloroform bark extracts, respectively, suggesting that the mechanism of action the extracts could be different from that of acyclovir, a known inhibitor of the viral DNA polymerase. Although a crude extract may contain several components endowed with antiviral activity each acting through a different mechanism some preliminary conclusions can be drawn on the main mode of antiviral action of the two extracts. The virucidal assay demonstrated that only the water bark extract has a direct virus-inactivating activity when HSV-2 was preincubated with the extract for 2 hours at 37°C. Interestingly, Yarmolinsky et al. published also indirect evidence for interactions between ethanol leaf extract of *Ficus binjamina* and HSV-1 and HSV-2 [20].

Since chloroform extract of *F. religiosa* did not inactivate extracellular virus particles, we explored if it could interfere with the early stages of viral infection. Time of addition assays showed that preincubation of cells with extract had no significant effect on the development of infection induced by virus, whereas when the cells were treated at the time of infection or post-infection, inhibition of HSV-2 was highest. The antiviral activity observed when the extract and the virus inoculum were added simultaneously to the cells, indicated that the extract may target early steps of viral replicative cycle such as virus attachment and/or entry. Performing specific assays, we demonstrated the ability of chloroform extract to inhibit both attachment and entry of virus. A significant reduction of the number of viral plaques was also observed when the extract was added to methylcellulose medium after infection. This finding suggests that the chloroform extract could be able to inhibit the cell-to-cell spread of virus. Similarly to *F. religiosa* chloroform bark extract, ethanol extract of *F. binjamina* showed a greatest anti-HSV-2 effect when it was added to cells at the time of infection and a partial inhibitory effect when added post-infection [20].

Summarizing the results, *F. religiosa* water bark extract inactivates extracellular virus particles, instead chloroform bark extract exerts multiple inhibitory activities on HSV-2 replicative cycle including the virus attachment to the cell surface, the virus entry into cells, and the viral plaque formation. Furthermore, it was also able to limit the development of viral cytopathic effect during ongoing infection.

All together these findings provide a basis for the identification of bioactive metabolites of *F. religiosa* as therapeutic natural compounds to treat genital herpetic ulcers also caused by acyclovir-resistant HSV-2 strains. Moreover, they

support the traditional use of *F. religiosa* bark applied externally for the treatment of ulcers and sores in genital diseases [7].

**Acknowledgments**

This study was supported by a donation from Silvana Legnani

**Compliance with ethical standards** *Conflict of interest* The authors declare that they have no conflict of interest

## References

- 1 [1] Galil J (1984) *Ficus religiosa* L. – the tree-splitter. Botanical Journal of the Linnean Society 88:185-203
- 2
- 3 [2] Aiyegoro OA, Okoh AI (2009) Use of bioactive plant products in combination with standard antibiotics,
- 4 implications in antimicrobial chemotherapy. Journal of Medicinal Plants Research 3:1147-1152
- 5
- 6 [3] Singh D, Singh B, Goel RK (2011) Traditional uses, phytochemistry and pharmacology of *Ficus religiosa*: A
- 7 review. Journal of Ethnopharmacology 134:565-583. doi: 10.1016/j.jep.2011.01.046
- 8
- 9 [4] Choudhari AS, Suryavanshi SA, Kaul-Ghanekar R (2013) The aqueous extract of *Ficus religiosa* induces cell cycle
- 10 arrest in human cervical cancer cell lines SiHa (HPV-16 Positive) and apoptosis in HeLa (HPV-18 Positive). PLoS
- 11 ONE 8:e70127 (1-10). doi: 10.1371/journal.pone.0070127
- 12
- 13 [5] Kusumoto IT, Nakabayashi T, Kida H, Miyashiro H, Hattori M, Namba T (1995) Screening of various plant extracts
- 14 used in ayurvedic medicine for inhibitory effects on human immunodeficiency virus type 1 (HIV-1) protease.
- 15 Phytotherapy Research 9:180-184
- 16
- 17 [6] Cagno V, Civra A, Kumar R, Pradhan S, Donalisio M, Nayan Sinha B, Ghosh M, Lembo D (2015a) *Ficus religiosa*
- 18 L. bark extracts inhibit human rhinovirus and respiratory syncytial virus infection *in vitro*. Journal of
- 19 Ethnopharmacology 176:252-257. doi: 10.1016/j.jep.2015.10.042
- 20
- 21 [7] Sharma HK, Chhange L, Dolui AK (2001) Traditional medicinal plants in Mizoram, India. Fitoterapia 72:146-161
- 22
- 23 [8] Roizman B, Knipe DM, Whitley RJ (2007) Herpes simplex viruses. In: Knipe DM et al (ed) Fields virology, 5th
- 24 edn. Lippincott, Williams & Wilkins, Philadelphia, pp 2501-2601
- 25
- 26 [9] Stanberry LR, Cunningham AL, Mindel A, Scott LL, Spruance SL, Aoki FY, Lacey CJ (2000) Prospects for control
- 27 of herpes simplex virus disease through immunization. Clinical Infectious Diseases 30:549-566
- 28
- 29 [10] Feng Z, Qiu Z, Sang Z, Lorenzo C, Glasser J (2013) Modeling the synergy between HSV-2 and HIV and potential
- 30 impact of HSV-2 therapy. Mathematical Biosciences 245:171-187. doi: 10.1016/j.mbs.2013.07.003
- 31
- 32 [11] Field HJ, Darby G, Wildy P (1980) Isolation and characterization of acyclovir resistant mutants of herpes simplex
- 33 virus. Journal of General Virology 49:115-124
- 34
- 35 [12] Donalisio M, Nana HM, Ngono Ngane RA, Gatsin D, Tiabou Tchinda A, Rovito R, Cagno V, Cagliero C, Boyom
- 36 FF, Rubiolo P, Bicchi C, Lembo D (2013) In vitro anti-Herpes simplex virus activity of crude extract of the roots of
- 37 *Nauclea latifolia* Smith (Rubiaceae). BMC Complementary and Alternative Medicine 13:266-274. doi: 10.1186/1472-
- 38 6882-13-266
- 39
- 40 [13] Cavalli R, Donalisio M, Bisazza A, Civra A, Ranucci E, Ferruti P, Lembo D (2012) Enhanced antiviral activity of
- 41 acyclovir loaded into nanoparticles. Methods of Enzymology 509:1-19. doi: 10.1016/B978-0-12-391858-1.00001-0
- 42
- 43 [14] Donalisio M, Cornaglia M, Landolfo S, Lembo D (2008) TGF-beta1 and IL-4 downregulate human
- 44 papillomavirus-16 oncogene expression but have differential effects on the malignant phenotype of cervical carcinoma
- 45 cells. Virus Research 132:253-266. doi: 10.1016/j.virusres.2007.12.003
- 46
- 47 [15] Cagno V, Donalisio M, Civra A, Cagliero C, Rubiolo P, Lembo D (2015b) *In vitro* evaluation of the antiviral
- 48 properties of Shilajit and investigation of its mechanisms of action. Journal of Ethnopharmacology 166:129-134. doi:
- 49 10.1016/j.jep.2015.03.019
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65

1 [16] Civra A, Cagno V, Donalisio M, Biasi F, Leonarduzzi G, Poli G, Lembo D(2014) Inhibition of pathogenic non-  
2 enveloped viruses by 25-hydroxycholesterol and 27-hydroxycholesterol. Scientific Reports 4:7487. doi:  
3 10.1038/srep07487  
4

5 [17] Wang G, Wang H, Song Y, Jia C, Wang Z, Xu H (2004) Studies on anti-HSV effect of *Ficus carica* leaves. *Zhong*  
6 *Yao Cai*. 27:754-56  
7

8 [18] Xu ZS, Chou GX, Wang ZT (2014) A new luteolin triglycoside from *Ficus ischnopoda* leaves. *Nat Prod Res*. 28:  
9 1052-1057. doi: 10.1080/14786419.2014.904307  
10

11 [19] Yarmolinsky L, Huleihel M, Zaccai M, Ben-Shabat S (2012) Potent antiviral flavone glycosides from *Ficus*  
12 *benjamina* leaves. *Fitoterapia* 83:362-367. doi: 10.1016/j.fitote.2011.11.014  
13  
14

15 [20] Yarmolinsky L, Zaccai M, Ben-Shabat S, Mills D, Huleihel M (2009) Antiviral activity of ethanol extracts of *Ficus*  
16 *binjamina* and *Lilium candidum* in vitro. *N Biotechnol*. 26:307-313. doi: 10.1016/j.nbt.2009.08.005  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65



## LEGENDS OF FIGURES


1 **Fig. 1** Evaluation of virus inactivation by *F. religiosa* water bark extract (panel A) and chloroform bark extract (panel  
2 B) on infectious HSV-2 particles at 37°C for 0 or 2h. On the y axis, the infectious titers are expressed as plaque-forming  
3 units per mL (PFU/mL). Error bars represent the SEM of 3 independent experiments.  
4


5 **Fig. 2** Time-of-addition assays. Cells were treated with chloroform bark extract for 2h before infection (pre-treatment),  
6 for 1h during infection or by adding the extracts immediately after infection (post-infection). The virus titers in the  
7 treated samples are expressed as a percentage of the titer obtained in the control (DMSO treated).  
8  
9


10 **Fig. 3** HSV-2 entry and attachment assays. The chloroform bark extract of *F. religiosa* L. was added to the cell culture  
11 during virus-cell binding (attachment assay) or virus-cell penetration (entry assay). The number of infected cells in the  
12 treated samples is expressed as a percentage of control (DMSO treated). Each point represents mean and SEM for  
13 triplicates.  
14  
15

16 **Fig. 4** Viral yield reduction assay. The chloroform bark extract of *F. religiosa* was added to cell culture before, during,  
17 and after infection (panel A), or only after infection (panel B). When the cytopathic effect involved the whole  
18 monolayer of untreated cells, the supernatant was harvested and titrated. Viral titers (expressed as PFU/mL) are shown  
19 as means plus SEM for three independent experiments.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65









**Table 1. Phytochemical analysis of *F. religiosa* L. extracts**

Source	Extract	% Yield	Saponins	Carbohydrate	Alkaloids	Flavonoids	Tannins	Steroids
Leaves	Water	6.23	+	+	-	+	-	-
	Methanol	8.41	+	-	-	+	+	+
Bark	Ethylacetate	5.27	-	-	+	-	+	-
	Water	9.26	+	+	-	+	+	-
	Chloroform	8.14	-	-	+	-	+	+
	Methanol	10.24	+	-	-	+	+	+

**Table 2a. Antiviral activity of *F. religiosa* extracts against HSV-2**

Virus	Source	Extract	EC <sub>50</sub> * (µg/mL) – 95% C.I. #	EC <sub>90</sub> § (µg/mL) – 95% C.I.	CC <sub>50</sub> † (µg/mL)	SI‡
HSV-2	Leaves	Water	30.94 (27.73-34.53)	63.83 (49.52-82.28)	>2500	>80.8
		Methanol	13.29 (9.573-18.46)	26.54 (9.69-72.65)	1058	79.6
	Bark	Ethyl acetate	14.26 (5.35-38.06)	19.95 (2.13-187.0)	1057	74.1
		Water	9.76 (7.86-12.10)	18.39 (9.72-34.78)	1530	156.8
		Chloroform	6.09 (3.17-11.69)	22.87 (5.83-89.70)	809.6	132.9
		Methanol	5.20 (3.56-7.60)	9.15 (4.08-20.55)	161.8	31.1
	Reference drug	Acyclovir	0.64 (0.48-0.86)	3.17 (1.69-5.95)	>300	>468

**Table 2b. Antiviral activity of *F. religiosa* extracts against an acyclovir resistant HSV-2 strain**

Virus	Source	Extract	EC <sub>50</sub> * (µg/mL) – 95% C.I. #	EC <sub>90</sub> § (µg/mL) – 95% C.I.	SI‡
HSV-2 acyclovir resistant strain	Bark	Water	6.70 (4.56-9.80)	27.01 (11.91-61.24)	228.36
		Chloroform	13.50 (9.96-18.30)	23.74 (8.96-62.90)	59.97

EC<sub>50</sub>\* half maximal effective concentration

C.I. # confidence interval

EC<sub>90</sub>§ 90% effective concentration

CC<sub>50</sub>† half maximal cytotoxic concentration

SI‡ selectivity index